We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”...
Immatics Announces Second Quarter 2024 Financial Results and Business Update Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients...
Immatics Appoints Alise Reicin to Board of Directors Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage...
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage...
Immatics Announces First Quarter 2024 Financial Results and Business Update Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting...
Immatics Announces Full Year 2023 Financial Results and Corporate Update Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed...
Immatics Announces Pricing of $175 Million Public Offering Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage...
Immatics Announces Proposed Public Offering Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company...
Immatics Announces Third Quarter 2023 Financial Results and Business Update ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median...
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial Company to host conference call and webcast today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.97 | 9.24690181125 | 10.49 | 11.7 | 9.8 | 2609 | 10.68620079 | DE |
4 | -0.04 | -0.347826086957 | 11.5 | 12.01 | 9.8 | 1706 | 10.8734598 | DE |
12 | 0.44 | 3.99274047187 | 11.02 | 12.6 | 8.97 | 2364 | 10.89248926 | DE |
26 | -0.2 | -1.71526586621 | 11.66 | 12.6 | 6.86 | 2882 | 10.20374893 | DE |
52 | 1.16 | 11.2621359223 | 10.3 | 13.2 | 6.15 | 2897 | 10.22115861 | DE |
156 | 1.16 | 11.2621359223 | 10.3 | 13.2 | 6.15 | 2897 | 10.22115861 | DE |
260 | 0 | 0 | 0 | 11.7 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions